OraSure Technologies, Inc. (NASDAQ:OSUR)‘s stock had its “buy” rating reaffirmed by research analysts at Jefferies Group LLC in a research report issued to clients and investors on Friday. They currently have a $23.00 price objective on the medical instruments supplier’s stock. Jefferies Group LLC’s price objective would suggest a potential upside of 13.64% from the company’s previous close.

Several other equities analysts also recently commented on OSUR. Canaccord Genuity increased their target price on shares of OraSure Technologies from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, June 28th. Stephens reissued an “overweight” rating and set a $19.00 target price (up from $14.00) on shares of OraSure Technologies in a research report on Tuesday, July 11th. BidaskClub downgraded shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Finally, Zacks Investment Research downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Friday, September 8th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $18.54.

Shares of OraSure Technologies (NASDAQ:OSUR) traded up 3.37% on Friday, hitting $20.24. The company’s stock had a trading volume of 799,611 shares. The stock has a market capitalization of $1.20 billion, a P/E ratio of 37.41 and a beta of 1.55. OraSure Technologies has a 52 week low of $7.09 and a 52 week high of $23.01. The stock’s 50 day moving average price is $21.67 and its 200 day moving average price is $17.74.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.07 by $0.02. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The business had revenue of $40.18 million for the quarter, compared to the consensus estimate of $36.54 million. During the same period in the prior year, the business posted $0.07 earnings per share. OraSure Technologies’s revenue for the quarter was up 28.1% compared to the same quarter last year. On average, analysts forecast that OraSure Technologies will post $0.48 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/10/21/orasure-technologies-inc-osur-given-buy-rating-at-jefferies-group-llc.html.

In other OraSure Technologies news, CEO Douglas A. Michels sold 22,923 shares of the stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $23.00, for a total transaction of $527,229.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Brian Smith sold 9,112 shares of the stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $20.47, for a total transaction of $186,522.64. Following the transaction, the insider now directly owns 32,477 shares in the company, valued at $664,804.19. The disclosure for this sale can be found here. Insiders have sold 717,601 shares of company stock worth $14,977,398 over the last three months. Company insiders own 6.40% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its position in shares of OraSure Technologies by 127,593.4% in the first quarter. BlackRock Inc. now owns 7,743,325 shares of the medical instruments supplier’s stock valued at $100,123,000 after purchasing an additional 7,737,261 shares during the last quarter. Vanguard Group Inc. grew its position in shares of OraSure Technologies by 19.8% in the second quarter. Vanguard Group Inc. now owns 5,352,832 shares of the medical instruments supplier’s stock valued at $92,390,000 after purchasing an additional 886,333 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of OraSure Technologies by 5.8% in the second quarter. Dimensional Fund Advisors LP now owns 3,057,690 shares of the medical instruments supplier’s stock valued at $52,777,000 after purchasing an additional 167,642 shares during the last quarter. Daruma Capital Management LLC grew its position in shares of OraSure Technologies by 2,761.0% in the second quarter. Daruma Capital Management LLC now owns 2,821,506 shares of the medical instruments supplier’s stock valued at $48,699,000 after purchasing an additional 2,722,886 shares during the last quarter. Finally, Acadian Asset Management LLC grew its position in shares of OraSure Technologies by 32.5% in the second quarter. Acadian Asset Management LLC now owns 1,846,854 shares of the medical instruments supplier’s stock valued at $31,877,000 after purchasing an additional 452,642 shares during the last quarter. 92.07% of the stock is currently owned by hedge funds and other institutional investors.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Analyst Recommendations for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.